AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02307591
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
Trial: NCT01949233
Drug: Doxycycline 100-200mg capsules daily for 6 months
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01949233
Drug: Doxycycline placebo capsules daily for 6 months
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03891472
Drug: Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
Trial: NCT01104246
Drug: Testerone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone applied daily for 4 weeks
Trial: NCT00483834
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
Trial: NCT01379976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
Trial: NCT04446845
Drug: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Trial: NCT04446845
Drug: Conventional Stimulation (Elonva+rFSH) in follicular phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Trial: NCT04612881
Drug: fitostimoline vaginal pessaries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal pessaries
Trial: NCT01226901
Drug: MK-4827
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
Trial: NCT03515382
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of GLPG1690.
Trial: NCT00307632
Drug: Norelgestromine (NLGM)/ethinyl estradiol (EE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
Trial: NCT00175032
Drug: Lansoprazole and naproxen and aspirin
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00175032
Drug: Celecoxib and aspirin
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT03034018
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken at bedtime for four weeks
Trial: NCT01905501
Drug: Balanced anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
Trial: NCT01905501
Drug: Total intravenous anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
Trial: NCT01301781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI801 placebo - oral solution
Trial: NCT00953537
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04738422
Drug: Alkaline glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
Trial: NCT03889470
Drug: NTG 1 MG/ML Injectable Solution
RxNorm normalized name: NTG 1 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered after sheath placement
Trial: NCT00432081
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01036022
Drug: GSK1399686
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
Trial: NCT01902758
Drug: ambrisentan and theophylline
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01902758
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for comparison group
Trial: NCT05642624
Drug: Deoxycholic acid amphotericin B
RxNorm normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
Trial: NCT01425970
Drug: Placebo matching with INX-08189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
Trial: NCT03642860
Drug: Placebo Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
Trial: NCT00612534
Drug: Sufentanil NanoTab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Trial: NCT00612534
Drug: Sufentanil NanoTab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Trial: NCT00612534
Drug: Sufentanil NanoTab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Trial: NCT02378415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Infusion
Trial: NCT01721915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00157911
Drug: Comparator: simvastatin / Duration of Treatment: 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03023111
Drug: Sbv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for CL, parenteral drug used during 20 days.
Trial: NCT02243241
Drug: Placebo for HYD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match HYD tablets administered orally every 24 hours.
Trial: NCT00511979
Drug: Regular human insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00250458
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose matching placebo to Rizatriptan to treat one migraine attack.
Trial: NCT03613558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT02026817
Drug: HCP1201 750/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Trial: NCT02026817
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Trial: NCT01286441
Drug: 10% EISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Trial: NCT01286441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Trial: NCT01286441
Drug: 20% EISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Trial: NCT01103102
Drug: Iocide Oral Rinse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
Trial: NCT01103102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01286441
Drug: 30% EISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Trial: NCT03017326
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms C, D and E used in combination
Trial: NCT00711828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01756105
Drug: Rapid acting analog insulin Intermediate acting NPH Insulin
RxNorm normalized name: Insulins and analogs for injection, intermediate-acting combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
Trial: NCT03017326
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm C used alone
Trial: NCT03603951
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
Trial: NCT03051698
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vancomycin, ciprofloxacin, metronidazole
Trial: NCT01196689
Drug: AZD1981 100 mg twice daily for 61/2 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablets
Trial: NCT01801358
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
Trial: NCT01801358
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
Trial: NCT01918033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to desloratadine 5 mg tablets
Trial: NCT03265132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sub cutaneous injection
Trial: NCT01407874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose administered daily for 84 days.
Trial: NCT00088166
Drug: placebo hCRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo hCRF 2mg/day and open-label dexamethasone that they are taking
Trial: NCT02137785
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Trial: NCT01844206
Drug: Epidural Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
Trial: NCT03114215
Drug: MD1003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules 100mg 3 times per day
Trial: NCT00691899
Drug: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; oral, once daily for Approximately 36 months
Trial: NCT03114215
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules 100mg lactose 3 times per day
Trial: NCT01735214
Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Trial: NCT03912818
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03912818
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00431665
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02400567
Drug: Fluorouracile
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02400567
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01397539
Drug: BIIB037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
Trial: NCT05706090
Drug: fentanyl will be added
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
Trial: NCT02968433
Drug: Infusions of young plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
Trial: NCT03287414
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
Trial: NCT03287414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously every 4 weeks for 48 weeks
Trial: NCT03287414
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
Trial: NCT00546676
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03817411
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
Trial: NCT00836602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Once daily, 7 days
Trial: NCT00161070
Drug: anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01865916
Drug: Polyethylene Glycol (PEG) + ascorbic acid
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take split dose of 2L PEG and vitamin C
Trial: NCT01960530
Drug: Hydrocortisone granules
RxNorm normalized name: hydrocortisone Granule Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-particulate granules
Trial: NCT01960530
Drug: Hydrocortisone Tablet
RxNorm normalized name: Hydrocortisone Tablets
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard hydrocortisone tablets
Trial: NCT01960530
Drug: i.v. Hydrocortisone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydrocortisone solution for intravenous injection
Trial: NCT01301274
Drug: hypotonic
RxNorm normalized name: Hypotonic Tears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% NaCl/5% dextrose IV maintenance fluids
Trial: NCT01301274
Drug: isotonic
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl/5% dextrose IV maintenance fluids
Trial: NCT04211415
Drug: DS-2741a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
Trial: NCT04211415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, subcutaneous injection administered weekly for 4 weeks
Trial: NCT03817411
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
Trial: NCT00570622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo once a day orally for 9 days
Trial: NCT00886834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Trial: NCT01430780
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02750475
Drug: Sunscreen Sport Lotion (BAY987516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)